Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Regarding the PTSC Annual SHM held on 1/28/2010

"YES, against. They would need to buy back 2-300 million shares at least to have any impact whatsoever. And I don't think even that will make any difference. The issue is not the outstanding shares. It is about business ability as demonstrated by income/profit."

Couldn't agree more. With so many outstanding shares, buyback even at current prices would hardly make a dent in the total. What difference have buybacks made to date?

Share
New Message
Please login to post a reply